恒瑞医药(01276)：HRS-6257片获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (01276) has received approval from the National Medical Products Administration for clinical trials of HRS-6257 tablets, aimed at treating acute and chronic pain, with no similar drugs approved in the domestic market [1] Company Summary - The clinical trial approval for HRS-6257 tablets is a significant milestone for Heng Rui Medicine, indicating progress in its drug development pipeline [1] - The total research and development investment for the HRS-6257 project has reached approximately 15.58 million yuan [1] Industry Summary - Currently, there are no approved drugs targeting the same mechanism as HRS-6257 in the domestic market, highlighting a potential market opportunity for Heng Rui Medicine [1]